McDowell, Bethany
Marr, Calum
Holmes, Clive
Edwards, Christopher J.
Cardwell, Christopher
McHenry, Michelle
Meenagh, Gary
McGuinness, Bernadette http://orcid.org/0000-0002-7028-5633
Funding for this research was provided by:
Alzheimer Society (Alzheimer's Society 318 (AS-PG-16-023))
Health and Social Care Northern Ireland (NA)
Article History
Received: 17 January 2022
Accepted: 23 November 2022
First Online: 9 December 2022
Declarations
:
: The RESIST study was performed in accordance with the Declaration of Helsinki. The RESIST study was approved by the West Midlands – Black County Research Ethics Committee (REC reference: 17/WM/0161). Research governance permission was also granted by local research and development departments in both Northern Ireland (BHSCT, NHSCT) and Southampton (UHS). All patients provided written informed consent prior to recruitment.
: Not applicable. This manuscript does not include details, images, or videos relating to an individual person.
: All authors have completed the ICMJE uniform disclosure form at ExternalRef removed and declare funding obtained from the Alzheimer’s Society and Health and Social Care Research and Development Northern Ireland. CE reports grants for research support from Abbvie, Biogen and Samsung for work that was not directly related to this research but was in the field of biological therapies. He was also paid consulting fees from Abbvie, GSK and Gilead for work that was not directly related to this research. CE discloses receiving payments from Abbvie, Pfizer, Biogen, Fresenius and Janssen for lectures/presentations in the last 3 years. MMcH reports receiving funding to attend conferences from a number of companies who produce anti-TNF medications over the last 3 years and discloses that registration fees were covered by UCB.